Laurie Ann Karl, MD
Obstetrics/Gynecology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Karl’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G70159 · Current
Licensed to practise in California · since 1990 · expires 2028-05-31 · Jefferson Medical College of Thomas Jefferson University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$11,536
Medicare paid this office $11,536 for 120 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 36 | $3,661 | $75 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 73 | $3,516 | $48 |
| Short return visit | 16 | $841 | $49 |
Who their Medicare patients are
120 Original Medicare patients in 2024. Average age 72 · Health risk score 0.60. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 37% · Cancer 14% · Coronary heart disease 11% · Depression 11% · Diabetes 10%.
The office billed $42,288, Medicare allowed $15,021 and paid $11,536; for 175 services of 18 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 120 | 175 | 72 | 0.60 | $42,288 | $11,536 |
| 2023 | 114 | 175 | 73 | 0.63 | $42,222 | $12,517 |
| 2022 | 93 | 165 | 73 | 0.73 | $39,978 | $11,909 |
| 2021 | 86 | 157 | 72 | 0.52 | $38,916 | $12,020 |
| 2020 | 66 | 100 | 73 | 0.77 | $27,313 | $7,258 |
| 2019 | 76 | 136 | 71 | 0.60 | $35,053 | $9,043 |
| 2018 | 56 | 99 | 73 | 0.66 | $25,212 | $6,764 |
| 2017 | 63 | 118 | 72 | 0.80 | $31,680 | $8,179 |
| 2016 | 63 | 113 | 72 | 0.71 | $27,243 | $7,907 |
| 2015 | 60 | 103 | 70 | 0.69 | $24,855 | $7,208 |
| 2014 | 55 | 91 | 72 | 0.61 | $20,787 | $5,688 |
| 2013 | 53 | 89 | 72 | 0.55 | $21,003 | $5,610 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Short return visit (20+ min) | 52 | $5,250 | $75 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 56 | $2,739 | $49 |
| Return visit (30+ min) | 12 | $1,434 | $120 |
2022: 3 services
| Short return visit (20+ min) | 51 | $4,973 | $78 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 52 | $2,520 | $48 |
| Return visit (30+ min) | 18 | $1,733 | $91 |
2021: 3 services
| Short return visit (20+ min) | 46 | $4,424 | $80 |
| Return visit (30+ min) | 19 | $2,441 | $106 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 49 | $2,402 | $49 |
2020: 3 services
| Short return visit (20+ min) | 29 | $2,475 | $63 |
| Return visit (30+ min) | 19 | $1,749 | $92 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 23 | $1,132 | $49 |
2019: 4 services
| Short return visit (20+ min) | 32 | $2,852 | $59 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 36 | $1,709 | $47 |
| Return visit (30+ min) | 14 | $1,257 | $90 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 13 | $714 | $55 |
2018: 3 services
| Short return visit (20+ min) | 31 | $2,837 | $59 |
| Return visit (30+ min) | 16 | $1,624 | $96 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 13 | $593 | $46 |
2017: 3 services
| Short return visit (20+ min) | 30 | $2,570 | $57 |
| Return visit (30+ min) | 14 | $1,347 | $96 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 22 | $1,010 | $46 |
2016: 3 services
| Short return visit (20+ min) | 27 | $2,285 | $57 |
| Return visit (30+ min) | 20 | $2,111 | $96 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 22 | $997 | $45 |
2015: 4 services
| Short return visit (20+ min) | 25 | $2,107 | $62 |
| Return visit (30+ min) | 12 | $1,364 | $97 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 21 | $1,000 | $48 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 12 | $698 | $58 |
2014: 3 services
| Short return visit (20+ min) | 25 | $1,913 | $56 |
| Return visit (30+ min) | 12 | $1,301 | $93 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 21 | $943 | $45 |
2013: 3 services
| Return visit (30+ min) | 20 | $1,700 | $85 |
| Short return visit (20+ min) | 25 | $1,662 | $57 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 14 | $635 | $45 |
Drugs they prescribed that Part D paid
$37,539
Pharmacies billed $37,539 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
206 generic and 44 brand-name prescriptions · $37,539 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 78 | $12,710 | $163 |
| Estradiol (Twice Weekly) | 39 | $4,787 | $123 |
| Yuvafem | 18 | $3,916 | $218 |
| Dotti | 12 | $1,902 | $158 |
| Progesterone | 27 | $1,151 | $43 |
Year by year
| 2024 | 250 | 79 | None | 18% | $37,539 |
| 2023 | 197 | 65 | 0% (0) | 28% | $40,420 |
| 2022 | 190 | 53 | 0% (0) | 36% | $36,199 |
| 2021 | 138 | 47 | 0% (0) | 24% | $28,572 |
| 2020 | 131 | 36 | 0% (0) | 18% | $25,098 |
| 2019 | 146 | 35 | None | 31% | $23,441 |
| 2018 | 120 | 34 | 0% (0) | 47% | $21,465 |
| 2017 | 122 | 35 | None | 35% | $24,949 |
| 2016 | 142 | 34 | 0% (0) | 51% | $22,351 |
| 2015 | 175 | 37 | None | 54% | $19,228 |
| 2014 | 172 | 37 | None | 50% | $18,934 |
| 2013 | 139 | 34 | 0% (0) | 56% | $16,931 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Estradiol | 49 | $11,615 | $237 |
| Estring | 15 | $8,472 | $565 |
| Yuvafem | 20 | $4,133 | $207 |
| Estradiol (Twice Weekly) | 20 | $3,107 | $155 |
| Progesterone | 20 | $478 | $24 |
2022: 4 drugs
| Estradiol | 48 | $11,908 | $248 |
| Estring | 17 | $9,177 | $540 |
| Estradiol (Twice Weekly) | 21 | $2,533 | $121 |
| Progesterone | 19 | $812 | $43 |
2021: 2 drugs
| Estradiol | 35 | $7,442 | $213 |
| Estring | 14 | $7,268 | $519 |
2020: 4 drugs
| Estradiol | 33 | $7,385 | $224 |
| Estring | 13 | $6,235 | $480 |
| Yuvafem | 15 | $3,359 | $224 |
| Estradiol (Twice Weekly) | 15 | $1,760 | $117 |
2019: 4 drugs
| Estradiol | 41 | $7,037 | $172 |
| Yuvafem | 11 | $2,002 | $182 |
| Vivelle-Dot | 13 | $1,846 | $142 |
| Estradiol-Norethindrone Acetat | 13 | $1,462 | $112 |
2018: 4 drugs
| Estring | 11 | $4,841 | $440 |
| Estradiol | 12 | $2,130 | $178 |
| Vivelle-Dot | 15 | $2,095 | $140 |
| Valacyclovir | 14 | $902 | $64 |
2017: 5 drugs
| Premarin | 16 | $5,560 | $347 |
| Yuvafem | 12 | $4,427 | $369 |
| Estrace | 13 | $3,717 | $286 |
| Progesterone | 12 | $1,378 | $115 |
| Valacyclovir | 16 | $521 | $33 |
2016: 6 drugs
| Vagifem | 12 | $4,971 | $414 |
| Estrace | 12 | $3,168 | $264 |
| Vivelle-Dot | 16 | $3,122 | $195 |
| Valacyclovir | 15 | $956 | $64 |
| Estradiol | 15 | $802 | $53 |
| Progesterone | 14 | $771 | $55 |
2015: 5 drugs
| Vagifem | 13 | $4,212 | $324 |
| Vivelle-Dot | 23 | $3,739 | $163 |
| Progesterone | 37 | $2,626 | $71 |
| Estradiol | 28 | $2,590 | $92 |
| Fluconazole | 14 | $158 | $11 |
2014: 6 drugs
| Vagifem | 22 | $5,204 | $237 |
| Vivelle-Dot | 30 | $4,624 | $154 |
| Estrace | 13 | $2,184 | $168 |
| Estradiol | 26 | $1,154 | $44 |
| Progesterone | 16 | $958 | $60 |
| Fluconazole | 13 | $122 | $9 |
2013: 4 drugs
| Vivelle-Dot | 37 | $4,539 | $123 |
| Progesterone | 23 | $2,019 | $88 |
| Vagifem | 11 | $1,798 | $163 |
| Estradiol | 15 | $909 | $61 |
Money from drug and device companies
$125 in 2024
A payment is not proof that care is biased.
| Mayne Pharma Commercial | Nextstellis | $125 | 1 payment
|
See the published payment
| Mayne Pharma Commercial | Meals · 2024-03-20 | Nextstellis | $125 |
Professional record
- NPI
- 1720147184
- Licence
- CA G70159California G70159: Current · expires 2028-05-31
- Trained
- Jefferson Medical College of Thomas Jefferson University, 1988
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-12-08
- NPI last updated
- 2020-03-04
- NPI record certified
- 2020-03-04
This is when the NPI record was last certified, not a medical board exam.